全文获取类型
收费全文 | 665篇 |
免费 | 65篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 44篇 |
妇产科学 | 34篇 |
基础医学 | 90篇 |
口腔科学 | 13篇 |
临床医学 | 89篇 |
内科学 | 111篇 |
皮肤病学 | 11篇 |
神经病学 | 84篇 |
特种医学 | 11篇 |
外科学 | 55篇 |
综合类 | 7篇 |
一般理论 | 1篇 |
预防医学 | 86篇 |
眼科学 | 1篇 |
药学 | 32篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 9篇 |
2022年 | 14篇 |
2021年 | 26篇 |
2020年 | 32篇 |
2019年 | 28篇 |
2018年 | 31篇 |
2017年 | 21篇 |
2016年 | 24篇 |
2015年 | 31篇 |
2014年 | 34篇 |
2013年 | 44篇 |
2012年 | 45篇 |
2011年 | 50篇 |
2010年 | 28篇 |
2009年 | 21篇 |
2008年 | 40篇 |
2007年 | 45篇 |
2006年 | 31篇 |
2005年 | 27篇 |
2004年 | 34篇 |
2003年 | 29篇 |
2002年 | 24篇 |
2001年 | 6篇 |
2000年 | 8篇 |
1999年 | 3篇 |
1998年 | 4篇 |
1997年 | 5篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1965年 | 2篇 |
排序方式: 共有731条查询结果,搜索用时 15 毫秒
71.
Plasma kallikrein and FXIIa were assayed in acetone-treated human citrated plasma (CPLa) with the chromogenic peptide Bz-Ile-Glu-Gly-Arg-pNA (S-2222) as substrate. In end point assays with short incubation periods (1–10 min.) nearly all kallikrein present could be blocked by a low concentration of soybean trypsin inhibitor (STI). In 30 min. assays the main part of the kallikrein was recovered in a functional state not inhibited by STI, and at the same time the level of FXIIa (as amidase activity blocked by corn inhibitor, C.I.) was reduced to about 2/3 of the initial value. The formation of an association between FXIIa and kallikrein is suggested. In fractions from gel filtration of CPLa kallikrein was assayed as S-2302 amidase, high molecular weight kininogen (HK) was measured in rocket immunoassays, and HK and FXII were studied in PAGE immunoblot experiments. Kallikrein appeared as one peak together with HK (gel mol. wt. 300 KD), about 40% of HK was free (220 KD), and no FXII was observed in the kallikrein or HK peaks, but in two areas corresponding to 78–79 KD and 39–42 KD. When experiments, however, were carried out with plasma acetone-activated and gel filtered in the presence of benzamidine (5 mM), part of the amidase activity present in kallikrein peak fractions was blocked by C.I. This observation supports the above suggestion of an association between FXIIa and kallikrein. 相似文献
72.
Ronald M Krauss Patty W Siri 《Endocrinology & Metabolism Clinics of North America》2004,33(2):405-415
Increased plasma triglyceride and reduced high-density lipoprotein cholesterol are key features of the metabolic syndrome. Although elevated low-density lipoprotein cholesterol is not an integral characteristic of this syndrome, there is commonly an increase in the proportion of small, dense low-density lipoprotein particles. Together, these abnormalities constitute the atherogenic dyslipidemia of the metabolic syndrome. This article reviews the pathophysiology of altered triglyceride and low-density lipoprotein metabolism in the metabolic syndrome, outlines the relationship of these lipoprotein abnormalities to increased risk of coronary heart disease,and highlights the application of this information to clinical practice.The role of reduced high-density lipoprotein in the metabolic syndrome is discussed elsewhere in this issue. 相似文献
73.
Annalisa Siri Enrica Balza Barbara Gaggero Luciano Zardi 《Methods in Cell Science》1994,16(3-4):201-204
Summary We describe a purification procedure of human tenascin from conditioned medium of SK-MEL-28 melanoma cell line which involves the use of a hydroxyapatite chromatography column followed by polyethyleneglycol precipitation of crude tenascin eluted from the hydroxyapatite column. This procedure does not involve the use of specific antibodies and can thus be applied to culture media of cells of different species. 相似文献
74.
Brain changes associated with thromboxane receptor antagonist SQ 29,548 treatment in a mouse model 下载免费PDF全文
Andrew A. Rebel Siri A. Urquhart Kendra L. Puig Atreyi Ghatak Stephen A. Brose Mikhail Y. Golovko Colin K. Combs 《Journal of neuroscience research》2015,93(8):1279-1292
The purpose of this study was to characterize behavioral and physiological effects of a selective thromboxane (TP) receptor antagonist, SQ 29,548, in the C57Bl/6 mouse model. At 6 months of age, male mice were given either sham or drug i.p. injections for 3 days at a dose of 2 mg/kg each day. On the day after the final injection, mice were subjected to behavioral testing before brain collection. Left hemisphere hippocampi were collected from all mice for protein analysis via Western blot. Right brain hemispheres were fixed and embedded in gelatin and then serially sectioned. The sections were immunostained with anti‐c‐Fos antibodies. Prostaglandin analysis was performed from remaining homogenized brain samples, minus the hippocampi. Injection of SQ 29,548 decreased selective brain prostaglandin levels compared with sham controls. This correlated with robust increases in limbic‐region c‐Fos immunoreactivity in the SQ 29,548‐injected mice. However, drug‐treated mice demonstrated no significant changes in relevant hippocampal protein levels compared with sham treatments, as determined from Western blots. Surprisingly, injection of SQ 29,548 caused mixed changes in parameters of depression and anxiety‐like behavior in the mice. In conclusion, the results indicate that administration of peripheral TP receptor antagonists alters brain levels of prostanoids and influences neuronal activity, with only minimal alterations of behavior. Whether the drug affects neurons directly or through a secondary pathway involving endothelium or other tissues remains unclear. © 2015 Wiley Periodicals, Inc. 相似文献
75.
76.
77.
78.
Measures of body fat and related factors in normal adults. I. Introduction and methodology 总被引:3,自引:0,他引:3
R C Steinkamp N L Cohen W E Siri T W Sargent H E Walsh 《Journal of chronic diseases》1965,18(12):1279-1291
79.
Noam Yarom Anura Ariyawardana Allan Hovan Andrei Barasch Virginia Jarvis Siri Beier Jensen Yehuda Zadik Sharon Elad Joanne Bowen Rajesh V. Lalla 《Supportive care in cancer》2013,21(11):3209-3221
Purpose
The aim of this study was to review the available literature and define clinical practice guidelines for the use of natural agents for the prevention and treatment of oral mucositis.Methods
A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology. The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, and no guideline possible.Results
A total of 49 papers across 15 interventions were examined. A new suggestion was developed in favor of systemic zinc supplements administered orally in the prevention of oral mucositis in oral cancer patients receiving radiation therapy or chemoradiation (Level III evidence). A recommendation was made against the use of intravenous glutamine for the prevention of oral mucositis in patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplant (Level II evidence). No guideline was possible for any other agent, due to inadequate and/or conflicting evidence.Conclusions
Of the various natural agents reviewed here, the available evidence supported a guideline only for two agents: a suggestion in favor of zinc and a recommendation against glutamine, in the treatment settings listed above. Well-designed studies of other natural agents are warranted. 相似文献80.
Siri A. Eikeland Knut B. Smeland Mette Brekke Cecilie E. Kiserud Alexander Foss 《Scandinavian journal of primary health care》2022,40(3):360
ObjectiveWith increasing cancer incidence and survival rates, follow-up care becomes a major healthcare concern, placing increased demands on general practitioners (GPs). We explored GPs’ awareness of late effects (LEs) after cancer treatment. Their degree of involvement and attitudes towards follow-up care was studied separately for solid cancers and Hodgkin’s lymphoma (HL).Design and settingMailed questionnaire study in Norwegian general practice.Subjects185 responding GPs with responsibility for HL survivors, more than 10 years since diagnosis.Main outcome measures and resultsAll GPs reported some awareness of LEs. Increasing awareness of LEs was associated with female sex, being a specialist, having experience from hospital-based cancer care and familiarity with official guidelines on LEs after treatment. The majority of GPs were involved in follow-up care, which increased with patients’ time since treatment and was associated with higher awareness of LEs. GPs with work experience in hospital-based cancer care were more likely to be engaged in HL follow-up. Most GPs were willing to provide follow-up care at some point after treatment. Older and more experienced GPs, and those satisfied with the collaboration with hospital specialists, were more likely to provide follow-up earlier.ConclusionGPs’ awareness of LEs and their willingness to provide follow-up care were related to familiarity with guidelines and experience. GPs more involved in follow-up care also had higher knowledge of LEs. Distribution of guidelines on LEs and follow-up care, and improving collaboration with hospital specialists, might increase GPs’ knowledge and willingness to become involved in follow-up care, especially early in their careers. GPs’ involvement and attitude towards follow-up of survivors of common solid cancers and HL, a rare malignant disease, were similar.
KEY POINTS
- Norwegian general practitioners (GPs) are involved in survivorship care after cancer treatment. We investigated their awareness of late effects (LEs), their involvement and their attitude towards follow-up care of solid cancers and Hodgkin’s lymphoma. • GPs registered as specialists, aware of guidelines and with experience from hospital-based cancer care reported higher awareness of LEs.
- • GPs with higher awareness of LEs were more frequently involved in follow-up care.
- • GPs with longer experience in general practice were comfortable with follow-up care at an earlier stage after treatment.
- • Results were similar for follow-up care of survivors of solid cancers and Hodgkin’s lymphoma.